Medicine and Dentistry
Adverse Event
6%
Arm
6%
Atazanavir
6%
Atazanavir Plus Ritonavir
20%
Cardiovascular Disease
6%
Chemotherapeutic Agent
6%
Chronic Kidney Disease
100%
Clinician
6%
Decision Making
6%
Development
13%
Drug
6%
Drug Use
6%
Female
6%
Follow up
26%
Gender
6%
Glomerular Filtration Rate
26%
Health
6%
Hepatitis C
6%
High Risk Population
6%
Hospital
6%
Human Immunodeficiency Virus
26%
Human Immunodeficiency Virus Infection
13%
Hypertension
6%
Incidence
13%
Lopinavir/Ritonavir
20%
Low Risk Population
6%
Mixed Infection
6%
Morbidity
6%
Mortality
6%
Number Needed to Harm
20%
Patient
6%
Person
6%
Proteinase Inhibitor
13%
Proteinuria
6%
Race
6%
Senescence
6%
Tenofovir
13%
Therapeutic Procedure
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
6%
Anti-Human Immunodeficiency Virus
13%
Atazanavir
6%
Atazanavir Plus Ritonavir
20%
Chronic Kidney Failure
100%
Diabetes Mellitus
6%
Drug
6%
Hepatitis C
6%
HIV
26%
Human Immunodeficiency Virus Infection
13%
Hypertension
6%
Incidence
13%
Lopinavir Plus Ritonavir
20%
Mixed Infection
6%
Morbidity
6%
Mortality
6%
Number Needed to Harm
20%
Proteinase Inhibitor
13%
Proteinuria
6%
Tenofovir
13%